

# Giovanna Schiavoni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1981047/publications.pdf>

Version: 2024-02-01

55  
papers

5,642  
citations

172457

29  
h-index

189892

50  
g-index

58  
all docs

58  
docs citations

58  
times ranked

9303  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multi-scale generative adversarial network for improved evaluation of cell-cell interactions observed in organ-on-chip experiments. <i>Neural Computing and Applications</i> , 2021, 33, 3671-3689.	5.6	13
2	A Clonogenic Assay to Quantify Melanoma Micrometastases in Pulmonary Tissue. <i>Methods in Molecular Biology</i> , 2021, 2265, 385-406.	0.9	0
3	Oncoimmunology Meets Organs-on-Chip. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 627454.	3.5	21
4	Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments. <i>Journal of Visualized Experiments</i> , 2021, , .	0.3	5
5	Anticancer Effects of Sublingual Type I IFN in Combination with Chemotherapy in Implantable and Spontaneous Tumor Models. <i>Cells</i> , 2021, 10, 845.	4.1	4
6	Editorial: Emerging Roles for Type 2-Associated Cells and Cytokines in Cancer Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 811125.	4.8	3
7	High-throughput analysis of cell-cell crosstalk in ad hoc designed microfluidic chips for oncoimmunology applications. <i>Methods in Enzymology</i> , 2020, 632, 479-502.	1.0	7
8	Is There a Role for Basophils in Cancer?. <i>Frontiers in Immunology</i> , 2020, 11, 2103.	4.8	37
9	Anti-Tumorigenic Activities of IL-33: A Mechanistic Insight. <i>Frontiers in Immunology</i> , 2020, 11, 571593.	4.8	19
10	Eosinophils in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1273, 1-28.	1.6	20
11	Accelerating the experimental responses on cell behaviors: a long-term prediction of cell trajectories using Social Generative Adversarial Network. <i>Scientific Reports</i> , 2020, 10, 15635.	3.3	8
12	Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade. <i>Cells</i> , 2020, 9, 940.	4.1	8
13	Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Na <sup>+</sup> ve/Memory T Cell Immunomonitoring. <i>Journal of Immunology Research</i> , 2020, 2020, 1-15.	2.2	8
14	Basophils in Tumor Microenvironment and Surroundings. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1224, 21-34.	1.6	30
15	IL-33 Promotes CD11b/CD18-Mediated Adhesion of Eosinophils to Cancer Cells and Synapse-Polarized Degranulation Leading to Tumor Cell Killing. <i>Cancers</i> , 2019, 11, 1664.	3.7	45
16	From Petri Dishes to Organ on Chip Platform: The Increasing Importance of Machine Learning and Image Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 100.	3.5	26
17	Abstract A091: IL-33 activates antitumoral toxicity in eosinophils through stimulation of contact-dependent degranulation. , 2019, , .		0
18	Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells. <i>Cancer Immunology Research</i> , 2018, 6, 658-670.	3.4	34

#	ARTICLE	IF	CITATIONS
19	Eosinophils: The unsung heroes in cancer?. <i>Oncolmmunology</i> , 2018, 7, e1393134.	4.6	184
20	The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 2601.	4.8	74
21	The dangerous liaison between pollens and pollution in respiratory allergy. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 269-275.	1.0	72
22	IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. <i>Oncolmmunology</i> , 2017, 6, e1317420.	4.6	137
23	Organs on chip approach: a tool to evaluate cancer-immune cells interactions. <i>Scientific Reports</i> , 2017, 7, 12737.	3.3	69
24	Combining Type I Interferons and 5-Aza-2â€²-Deoxycytidine to Improve Anti-Tumor Response against Melanoma. <i>Journal of Investigative Dermatology</i> , 2017, 137, 159-169.	0.7	60
25	Late Breaking Abstract - Title: Air-born allergens modulate the immunological lung microenvironment. , 2017, , .		0
26	Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis. <i>Oncotarget</i> , 2016, 7, 59754-59765.	1.8	4
27	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. <i>Science</i> , 2015, 350, 972-978.	12.6	367
28	Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. <i>Cell Death and Differentiation</i> , 2014, 21, 15-25.	11.2	740
29	A multidisciplinary study using <i>in vivo</i> tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells. <i>Journal of Immunotoxicology</i> , 2014, 11, 337-346.	1.7	48
30	Cancer-driven dynamics of immune cells in a microfluidic environment. <i>Scientific Reports</i> , 2014, 4, 6639.	3.3	68
31	Novel allergic asthma model demonstrates ST2-dependent dendritic cell targeting by cypress pollen. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 686-695.e7.	2.9	22
32	<i>Mycobacterium tuberculosis</i> PstS1 amplifies IFN $\beta$ and induces IL17/IL22 responses by unrelated memory CD4 <sup>+</sup> T cells via dendritic cell activation. <i>European Journal of Immunology</i> , 2013, 43, 2386-2397.	2.9	21
33	Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment. <i>Lab on A Chip</i> , 2013, 13, 229-239.	6.0	126
34	TIM-3 as a molecular switch for tumor escape from innate immunity. <i>Frontiers in Immunology</i> , 2013, 3, 418.	4.8	7
35	The Tumor Microenvironment: A Pitch for Multiple Players. <i>Frontiers in Oncology</i> , 2013, 3, 90.	2.8	121
36	Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response. <i>Frontiers in Immunology</i> , 2013, 4, 483.	4.8	113

#	ARTICLE	IF	CITATIONS
37	The dual role of IRF8 in cancer immunosurveillance. <i>Oncolmunology</i> , 2013, 2, e25476.	4.6	7
38	Interferon Regulatory Factor 8-Deficiency Determines Massive Neutrophil Recruitment but T Cell Defect in Fast Growing Granulomas during Tuberculosis. <i>PLoS ONE</i> , 2013, 8, e62751.	2.5	6
39	IRF-8 Controls Melanoma Progression by Regulating the Cross Talk between Cancer and Immune Cells within the Tumor Microenvironment. <i>Neoplasia</i> , 2012, 14, 1223-IN43.	5.3	48
40	Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis. <i>Cancer Research</i> , 2011, 71, 768-778.	0.9	304
41	Type I IFNs Control Antigen Retention and Survival of CD8 <sup>+</sup> Dendritic Cells after Uptake of Tumor Apoptotic Cells Leading to Cross-Priming. <i>Journal of Immunology</i> , 2011, 186, 5142-5150.	0.8	110
42	Regulation of immune cell homeostasis by type I interferons. <i>Cytokine and Growth Factor Reviews</i> , 2010, 21, 227-236.	7.2	34
43	Type I IFN regulate DC turnover <i>in vivo</i> . <i>European Journal of Immunology</i> , 2009, 39, 1807-1818.	2.9	31
44	ICSBP/IRF-8 differentially regulates antigen uptake during dendritic-cell development and affects antigen presentation to CD4 <sup>+</sup> T cells. <i>Blood</i> , 2006, 108, 609-617.	1.4	25
45	STAT1 Regulates IFN- $\alpha$ - and IFN- $\beta$ -Dependent Control of Infection with <i>Chlamydia pneumoniae</i> by Nonhemopoietic Cells. <i>Journal of Immunology</i> , 2006, 176, 6982-6990.	0.8	41
46	IRF-1 deficiency skews the differentiation of dendritic cells toward plasmacytoid and tolerogenic features. <i>Journal of Leukocyte Biology</i> , 2006, 80, 1500-1511.	3.3	50
47	Type I IFN Protects Permissive Macrophages from <i>Legionella pneumophila</i> Infection through an IFN- $\beta$ -Independent Pathway. <i>Journal of Immunology</i> , 2004, 173, 1266-1275.	0.8	77
48	ICSBP is critically involved in the normal development and trafficking of Langerhans cells and dermal dendritic cells. <i>Blood</i> , 2004, 103, 2221-2228.	1.4	98
49	ICSBP Is Essential for the Development of Mouse Type I Interferon-producing Cells and for the Generation and Activation of CD8 <sup>+</sup> Dendritic Cells. <i>Journal of Experimental Medicine</i> , 2002, 196, 1415-1425.	8.5	389
50	Type I interferons produced by dendritic cells promote their phenotypic and functional activation. <i>Blood</i> , 2002, 99, 3263-3271.	1.4	446
51	Type I Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by Stimulating Dendritic Cells <i>In Vivo</i> . <i>Immunity</i> , 2001, 14, 461-470.	14.3	865
52	IL-15 Is Expressed by Dendritic Cells in Response to Type I IFN, Double-Stranded RNA, or Lipopolysaccharide and Promotes Dendritic Cell Activation. <i>Journal of Immunology</i> , 2001, 167, 1179-1187.	0.8	389
53	Cyclophosphamide induces type I interferon and augments the number of CD44 <sup>hi</sup> T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. <i>Blood</i> , 2000, 95, 2024-2030.	1.4	189
54	Traffic-related NO <sub>2</sub> affects expression of <i>Cupressus sempervirens</i> L. pollen allergens. <i>Annals of Agricultural and Environmental Medicine</i> , 0, , .	1.0	2

#	ARTICLE	IF	CITATIONS
55	Differential Effects of Alarmins on Human and Mouse Basophils. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	10